60 results about "Clostridium organisms" patented technology

A composition for treating a subject is provided. The composition includes antigen specific dimeric secretory IgA and pentameric IgM therapeutic. A process for manufacturing a medicament for the treatment of C. difficile associated disease in a human is also provided that the modification of antigen specific dimeric secretory IgA and pentameric IgM with secretory component to form a antigen specific dimeric secretory IgA and pentameric secretory IgM therapeutic. The antigen specific dimeric secretory IgA and the pentameric secretory IgM therapeutic is then mixed with formulating agents to create a capsule, tablet, liquid or suppository dosing form. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating. A method of C. difficile treatment with the therapeutic is also provided that is amenable to supplementation with concurrent or prior antibiotic administration.

The invention relates to a method for a tetanus toxin receptor binding domain Hc to be subjected to high-level soluble expression in Escherichia coli through nucleotide sequence optimization. According to the sequencing result of a domestic C.Tetani virulent strain CMCC64008, the tetanus toxin receptor binding domain Hc sequence is analyzed and optimized, the optimized sequence is SEQ ID No.1 and the coded protein sequence is SEQ ID No.2. The synthesized Hc gene is linked into an expression vector pET32a(+) after undergoing double enzyme digestion, the recombinant Hc is subjected to high soluble expression in Escherichia coli and the target protein accounts for about 46% of the total protein in the supernatant undergoing bacteriociasis. After QFF column purification, phenyl hydrophobic column purification and SP column purification, the purity of the target protein can be more than 95% and the yield thereof is more than 300mg/L. The recombinant protein prepared by the method of the invention has good immunogenicity, can induce the mice to produce high-titre protective antibodies and can resist attack of high-dose lethal toxins. The method has extensive application prospect in large-scale high-level preparation of the tetanus toxin recombinant subunit vaccine Hc.

The invention relates to HSDH (hydroxysteroid dehydrogenase), in particular to a gene S1-a-1 of novel 7 alpha-HSDH. A nucleotide sequence of the gene is shown as SEQ ID NO.2, the novel 7 alpha-HSDH is encoded, a nucleotide sequence of the novel 7 alpha-HSDH is shown as SEQ ID NO.1, the novel 7 alpha-HSDH can be used for catalyzing CDCA (chenodeoxycholic acid) and TCDCA (taurochenodeoxycholic acid) to generate 7K-LCA (7-ketone lithocholic acid) and T7K-LCA (taurine-7-ketone lithocholic acid), wherein the catalytic activity of the novel 7 alpha-HSDH for CDCA is about 5 times of that of 7 alpha-HSDH of Sardinia clostridium, and the catalytic activity of the novel 7 alpha-HSDH for TCDCA is about over 2.5 times of that of 7 alpha-HSDH of Sardinia clostridium, therefore, the novel 7 alpha-HSDH has a great industrial application value.

A Clostridium histolyticum collagenase ColH (Glu451Asp) melts adipose tissue when injected into selected regions of the body. This protein product melts fat pads effectively in fat rat experiments, with very little side effects. Very little hemorrhage was observed. We also invent a new version of ColH mutant by linking a peptide motif CKGGRAKDC-G(varying from 2 to 6 Gs) (SEQ ID NO: 2) in front of ColH (Glu451Asp) (called topical ColH-FM), which can target to white fat vasculature. By combining with novel transdermal technology (such as Hydroxysome technology), we develop a topical protein cream that can melt fat. This product can be used as cellulite cream and for chemical liposuction. This topical ColH-FM can also be injected into adipose tissue as a replacement for liposuction or as an adjunct method with liposuction. Since raise scar is formed by overgrowth of collagen, our topical ColH-FM cream is shown to have application in scar reduction.

The invention discloses recombinant alpha protein for inhibiting clostridium perfringens infection and a preparation method and application thereof. The recombinant alpha protein is shown in (a) or (b) or (c), wherein the protein in (a) is composed of amino acid sequences shown as SEQ ID No.2; the protein in (b) is composed of amino acid sequences shown at the sites No.51-No.353 of SEQ ID No.2; the fusion protein in (c) is obtained by fusing protein tags at carboxyl terminals or/and amino terminals of the protein shown in (a) or (b). The recombinant alpha protein enables animals to have a higher serum antibody level and resist attack of clostridium perfringens after the animals are immunized with the recombinant alpha protein. The recombinant alpha protein is good in solubility and easy to purify and can serve as a diagnostic antigen to be prepared into a monoclonal antibody or be used for further research on protein functions and conformation relations.

The invention relates to hydroxysteroid dehydrogenase, in particular to a new 7alpha-hydroxysteroid dehydrogenase gene Y1-a-1. The nucleotide sequence of the gene is as shown in SEQ ID NO. 2. New 7alpha-hydroxysteroid dehydrogenase is coded, and the amino acid sequence of new 7alpha-hydroxysteroid dehydrogenase is as shown in SEQ ID NO.1; new 7alpha-hydroxysteroid dehydrogenase can catalyze chenodeoxycholic acid (CDCA) and taurochenodeoxycholic acid (TCDCA) to generate 7-ketone lithocholic acid (7K-LCA) and tauro 7-ketone lithocholic acid (T7K-LCA); the catalysis activity for CDCA or TCDCA is more than two times that of existing Sardinia clostridium 7alpha-HSDH, and the new 7alpha-hydroxysteroid dehydrogenase gene Y1-a-1 has an extremely large industrial application value.

The present invention relates to a method for the purification, concentration and identification of glycosylphosphatidylinositol anchored proteins (GPI-APs) from a biological sample (cells, tissues and/or blood/serum) in a patient or subject, including a human patient or subject. A new method to separate GPI-anchored glycoproteins, a class of glycoproteins found in all animal cells and fluids including serum, from other glycoproteins and proteins for the purpose of identifying potential biomarkers for various diseases, including cancer, especially breast cancer, vaginal cancer, endometrial cancer, uterine cancer, cervical cancer, pancreatic cancer and prostate cancer. The method uses the alpha-toxin from Clostridium septicum to separate GPI-anchored glycoproteins for identification and optionally quantification. The GPI-APs so obtained may be used to raise antibodies for inclusion in an immunosorbent assay for the diagnosis or the monitoring of therapy of cancer in a patient.

The invention provides a pichia pastoris surface co-display system based on cellulosome as well as a construction method and application of the pichia pastoris surface co-display system and belongs tothe technical fields of molecular biology, food and gene engineering. The system comprises anchoring protein and polyprotein display chassis protein, wherein the anchoring protein is saccharomyces cerevisiae cell wall protein Sed1p; and the polyprotein display chassis protein is artificial mini scaffold protein MixA2 of clostridium cellulosome. The pichia pastoris surface co-display system basedon cellulosome can realize polyprotein co-display on cell surfaces; heterologous protein for fusion expression of dockerin is prepared from recombinant bacteria, purification is not needed, multiple proteins can be displayed on cell surfaces by direct specific binding of dockerin on recombinant protein and cohesion on MixA2, and the preparation cost of recombinant protein can be saved effectively.

The invention relates to 7alpha-oxhydryl sterol dehydrogenase and an encoding gene and application thereof, and belongs to the technical field of biology. The 7alpha-oxhydryl sterol dehydrogenase is protein shown in SEQ ID NO.1 or protein with the same functions, obtained through substitution and/or deletion and/or addition of one or more amino acid residues of an amino acid sequence shown in theSEQ ID NO.1. The 7alpha-oxhydryl sterol dehydrogenase can catalyze an asymmetric reduction reaction of carbanyl groups of C7alpha-oxhydryl groups of taurocholic acid, glycocholic acid, taurochenodeoxycholic acid and glycochenodeoxycholic acid and catalyze an asymmetric reduction reaction of carbanyl groups and oxhydryl groups in benzoyl groups of ethyl benzoylformate. Compared with 7alpha-oxhydrylsterol dehydrogenase in clostridium sardiniense, the 7alpha-oxhydryl sterol dehydrogenase has higher catalytic activity and thermostability, and has very high industrial application value.

The invention is about the recombined toxin of the bacteria which can lead the food poisoning. The Hc-VT1B-SEA-VT2B-SEB linked by the linker sequence is from the gene Hc of the botulin A, the A gene: SEA and the B gene: SEB of Staphylococcus aureus, the VT1B and VT2B of E.Colli O 157. The serum antibody can anti above five bacteria toxin. So it can be used to produce the reagent box of recombined toxin to detect the food.

A vaccine for the treatment or prophylaxis of C. difficile associated disease comprises a C. difficile gene or a C. difficile peptide/polypeptide or a derivative or fragment or mutant or variant thereof which is immunogenic in humans. The gene encodes a C. difficile surface layer protein, SlpA or variant or homologue thereof. The peptide/polypeptide is a C. difficile surface layer protein, SlpA or variant or homologue thereof. The vaccine may comprise a chimeric nucleic acid sequence.

The invention discloses a recycling method for aquatic product processing leftovers. Belongs to the technical field of aquatic product processing. The method comprises the following steps: (1) chopping aquatic product processing leftovers, adding water for water bath treatment, and sterilizing to obtain a fermentation substrate; (2) adding an organic solution into the fermentation substrate, and inoculating a strain culture solution for fermentation culture; the strain culture solutions are respectively a clostridium butyricum culture solution and a pseudomonas stutzeri culture solution. The obtained fermentation product has high protein content, total amino acid content, unsaturated fatty acid content and non-protein nitrogen content.

The invention belongs to the technical field of biology. The invention relates to a recombinant protein which is formed by repeatedly connecting two sections of dominant epitopes of clostridium difficile membrane protein-glutamate dehydrogenase (GDH) in series, and in order to improve the expression quantity of the recombinant protein in Escherichia coli, Escherichia coli preferred codons are adopted to convert the amino acid sequence of the recombinant protein into a corresponding nucleotide sequence, and the nucleotide sequence is chemically synthesized and a recombinant expression vector is constructed. The invention also relates to a phage library established by immunizing a mouse with the recombinant protein, a corresponding GDH single-chain antibody scfv sequence is obtained through panning and screening, the obtained scfv sequence is constructed into a complete mouse IgG1 antibody sequence expression vector, a monoclonal antibody is expressed through transient HEK293F cells, the monoclonal antibody is purified, horse radish peroxidase (HRP) is marked respectively, and an optimal monoclonal antibody pairing combination is determined through an ELISA orthogonal experiment.

The present invention relates to novel endolysin polypeptides or fragments thereof which possess antimicrobial activity, preferably antibacterial activity against Clostridium perfringens. The invention also relates to a nucleic acid molecule encoding the endolysin polypeptide or fragment, a recombinant polynucleotide expression vector comprising such a nucleic acid molecule, as well as a host cell comprising such a nucleic acid molecule or comprising such a recombinant polynucleotide expression vector. The invention also relates to compositions and foodstuffs comprising the endolysin polypeptides or fragments and uses thereof in the treatment of diseases or disorders in animals.